Experience Leucine AI.
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System
Equipment Qualification

Equipment Qualification

View Detailed Analysis

Analytics Overview

44
Form 483s Issued
3
483s converted to WL
50
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
28 Aug 2024
Empower Pharmacy
Drugs
02 Aug 2024
ProRx LLC
Drugs
14 Jun 2024
Biocon Biosphere Limited
Drugs
04 Apr 2024
Cipla Limited
Drugs
19 Mar 2024
Qualgen, LLC
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Pratik S Upadhyay
4
0
Adam M True
2
0
Alexandra A Carrico
2
0
Adetutu M Gidado
2
2
Ana E Morales
2
0
TITLE/ COMPANY Issue Date Status Details
Equipment and utensils are not cleaned at appropriate intervals to prevent...
Granules India Limited
06 Sep 2024 Normal Justification: The mention of inadequate cleaning since installation suggests deficiencies in initial and ongoing equipment qualification.
Excerpt: Non-dedicated equipment used in the manufacturing of drug products at your firm have not been appropriately cleaned since their installation several years ago.
View Details
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Empower Pharmacy
28 Aug 2024 Normal Justification: Equipment Qualification issues are highlighted by scratches impacting aseptic nature of equipment.
Excerpt: Scratches were observed inside ISO-5 hoods that do not appear smooth and cleanable.
View Details
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance.
ProRx LLC
02 Aug 2024 Normal Justification: The observation explicitly mentions the lack of equipment qualification studies which is essential for ensuring equipment suitability and compliance.
Excerpt: firm failed to perform protocol driven equipment qualification studies for the following equipment...
View Details
Your firm failed to establish written procedures for production and process controls
Biocon Biosphere Limited
14 Jun 2024 Normal Justification: The issue directly pertains to the qualification of equipment (IQ/OQ/PQ), which is essential for ensuring they are suitable for their intended use in production.
Excerpt: The process validation report titled "Process Performance Qualification Report of (b) (4) API" MVD-000146683, ver 3.0, was executed using equipment that was not fully qualified (IQ/OQ/PQ).
View Details
Equipment qualification procedures are not followed
Cipla Limited
04 Apr 2024 Normal Justification: The observation directly relates to a failure in conducting required risk assessments and qualification activities for new equipment, pointing to a deficiency in executing the Equipment Qualification process as per the firm’s own standards.
Excerpt: Your firm did not follow procedure 1035-G-0042 - Qualification of Equipment...for pharmaceutical ingredient manufacture...has not conducted a risk assessment nor qualification activities for the
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.